Loganathan Rangasamy

10PUBLICATIONS
12CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Medicinal and biomolecular chemistry not elsewhere classifiedBiologically active moleculesMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 01, 2026
Hitting the bullseye: PSMA-targeted small molecule drug conjugate for prostate cancer treatment.

|Jul 14, 2026
Receptor-Targeted Folic Acid Ligand-Drug Conjugate of Exatecan Leads to Complete Tumor Regression in the Preclinical Tumor Model.

|Dec 30, 2025
Correction: Venkatesan et al. A Perspective on Newly Emerging Proteolysis-Targeting Strategies in Antimicrobial Drug Discovery. Antibiotics 2022, 11, 1717.

Janarthanan Venkatesan, Dhanashree Murugan, Loganathan Rangasamy

|May 20, 2025
New spirooxindole pyrrolidine/pyrrolizidine analogs: design, synthesis, and evaluation as an anticancer agent.

Narayanasamy Nivetha, Janarthanan Venkatesan, Dhanashree Murugan

|Jun 21, 2024
Siderophore-Conjugated Antifungals: A Strategy to Potentially Cure Fungal Infections.

Kalaiarasu Lakshminarayanan, Dhanashree Murugan, Janarthanan Venkatesan

|Apr 18, 2024
Synthesis and study of antibiofilm and antivirulence properties of flavonol analogues generated by palladium catalyzed ligand free Suzuki-Miyaura coupling against Pseudomonas aeruginosa PAO1.

Anjitha Theres Benny, Masthan Thamim, Prakhar Srivastava

Pageof 2

Frequent Collaborators

4 joint publications

Dhanashree Murugan

2 joint publications

Janarthanan Venkatesan

1 joint publications

Esteban A Orellana

1 joint publications

Srinivasarao Tenneti